{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:38:13Z","timestamp":1790095093265,"version":"4.0.1"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-01921-1","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:34:02Z","timestamp":1760247242000},"page":"6105-6165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent advances in treating age-related macular degeneration and diabetic retinopathy: Current therapies and emerging novel approaches"],"prefix":"10.1007","volume":"48","author":[{"given":"R\u00e9ka","family":"Antal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Beny\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n Zsolt","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ill\u00e9s","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos Tibor","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6251-1007","authenticated-orcid":false,"given":"Kriszti\u00e1n A.","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,12]]},"reference":[{"issue":"2","key":"1921_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"15","key":"1921_CR2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.15.47","volume":"64","author":"TY Wong","year":"2023","unstructured":"Wong TY, Tan TE. The diabetic retinopathy \u201cpandemic\u201d and evolving global strategies: the 2023 Friedenwald Lecture. Invest Ophthalmol Vis Sci. 2023;64(15):47.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1921_CR3","unstructured":"Grandviewresearch.com. San Francisco, CA: Grand View Research. Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/age-related-macular-degeneration-market-report. Published August 23, 2022. Accessed August 13, 2024."},{"key":"1921_CR4","unstructured":"Gminsights.com. Selbyville, DE: Global Market Insights. Available from: https:\/\/www.gminsights.com\/industry-analysis\/diabetic-retinopathy-market-report. Published April, 2019. Accessed August 13, 2024."},{"key":"1921_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.03.014","author":"RB Nussenblatt","year":"2014","unstructured":"Nussenblatt RB, Lee RWJ, Chew E, Wei L, Liu B, Sen HN, et al. Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention. Am J Ophthalmol. 2014. https:\/\/doi.org\/10.1016\/j.ajo.2014.03.014.","journal-title":"Am J Ophthalmol"},{"key":"1921_CR6","doi-asserted-by":"crossref","unstructured":"Khan AH, Chowers I, Lotery AJ. Beyond the complement cascade: insights into systemic immunosenescence and inflammaging in age-related macular degeneration and current barriers to treatment. Cells. 2023 Jul 1;12(13).","DOI":"10.3390\/cells12131708"},{"issue":"6","key":"1921_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194.","journal-title":"Cell"},{"key":"1921_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003794","author":"SR Kennedy","year":"2013","unstructured":"Kennedy SR, Salk JJ, Schmitt MW, Loeb LA. Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage. PLoS Genet. 2013. https:\/\/doi.org\/10.1371\/journal.pgen.1003794.","journal-title":"PLoS Genet"},{"issue":"11","key":"1921_CR9","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1167\/iovs.10-5429","volume":"51","author":"PP Karunadharma","year":"2010","unstructured":"Karunadharma PP, Nordgaard CL, Olsen TW, Ferrington DA. Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(11):5470\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"18","key":"1921_CR10","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1523\/JNEUROSCI.0190-15.2015","volume":"35","author":"MR Terluk","year":"2015","unstructured":"Terluk MR, Kapphahn RJ, Soukup LM, Gong H, Gallardo C, Montezuma SR, et al. Investigating mitochondria as a target for treating age-related macular degeneration. J Neurosci. 2015;35(18):7304\u201311.","journal-title":"J Neurosci"},{"issue":"60","key":"1921_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","volume":"1","author":"S Datta","year":"2017","unstructured":"Datta S, Cano M, Ebrahimi K, Wang L, Handa JT. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017;1(60):201\u201318.","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"1921_CR12","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0161-6420(86)33540-1","volume":"93","author":"F El Baba","year":"1986","unstructured":"El Baba F, Ii WHJ, Harbin TS, Fine SL, Michels RG, Schachat AP, et al. Massive haemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants. Ophthalmology. 1986;93(12):1581\u201392.","journal-title":"Ophthalmology"},{"issue":"1","key":"1921_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1006\/mvre.2002.2407","volume":"64","author":"A Otani","year":"2002","unstructured":"Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64(1):162\u20139.","journal-title":"Microvasc Res"},{"issue":"3","key":"1921_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","volume":"105","author":"CJ Thomas","year":"2021","unstructured":"Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021;105(3):473\u201391.","journal-title":"Med Clin North Am"},{"issue":"8","key":"1921_CR15","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jdi.13480","volume":"12","author":"KY Lin","year":"2021","unstructured":"Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12(8):1322\u20135.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"1921_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061816","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816.","journal-title":"Int J Mol Sci"},{"key":"1921_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.599281","volume":"8","author":"X Wang","year":"2020","unstructured":"Wang X, Bove AM, Simone G, Ma B. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol. 2020;8:599281.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1921_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/02713680701435391","volume":"32","author":"KC Silva","year":"2007","unstructured":"Silva KC, Pinto CC, Biswas SK, De Faria JBL, De Faria JML. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res. 2007;32(6):533\u201341.","journal-title":"Curr Eye Res"},{"issue":"3","key":"1921_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bcmd.2006.12.003","volume":"38","author":"ZK Otrock","year":"2007","unstructured":"Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38(3):258\u201368.","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"1921_CR20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097\u2013105.","journal-title":"Genes Cancer"},{"issue":"1","key":"1921_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jb\/mvs136","volume":"153","author":"M Shibuya","year":"2013","unstructured":"Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153(1):13\u20139.","journal-title":"J Biochem"},{"issue":"3","key":"1921_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1042\/CS20040370","volume":"109","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005;109(3):227\u201341.","journal-title":"Clin Sci"},{"issue":"20","key":"1921_CR23","first-page":"4575","volume":"55","author":"J Rak","year":"1995","unstructured":"Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF\/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res J. 1995;55(20):4575\u201380.","journal-title":"Cancer Res J"},{"issue":"4","key":"1921_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","volume":"18","author":"HA Elshabrawy","year":"2015","unstructured":"Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18(4):433\u201348.","journal-title":"Angiogenesis"},{"issue":"9","key":"1921_CR25","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1161\/CIRCRESAHA.116.310477","volume":"120","author":"K Heinolainen","year":"2017","unstructured":"Heinolainen K, Karaman S, Tammela T, Sormunen R, Eklund L, Alitalo K, et al. VEGFR3 modulates vascular permeability by controlling VEGF\/ VEGFR2 signaling HHS public access. Circ Res. 2017;120(9):1414\u201325.","journal-title":"Circ Res"},{"issue":"6","key":"1921_CR26","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1167\/iovs.12-10341","volume":"54","author":"S Nakao","year":"2013","unstructured":"Nakao S, Zandi S, Kohno RI, Sun D, Nakama T, Ishikawa K, et al. Lack of lymphatics and lymph node-mediated immunity in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54(6):3830\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1921_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1921_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312\u201324.","journal-title":"Res Synth Methods"},{"issue":"7","key":"1921_CR29","first-page":"583","volume":"88","author":"The Diabetic Retinopathy Study Research Group","year":"1981","unstructured":"The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Bull Soc Belge Ophtalmol. 1981;88(7):583\u2013600.","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"5","key":"1921_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(5):766\u201385.","journal-title":"Ophthalmology."},{"issue":"7","key":"1921_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/IAE.0b013e318042d32c","volume":"27","author":"DS Fong","year":"2007","unstructured":"Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007;27(7):816\u201324.","journal-title":"Retina"},{"issue":"8","key":"1921_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080069030","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","unstructured":"Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109(8):1109\u201314.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"1921_CR33","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/archopht.1993.01090090052019","volume":"111","author":"Macular Photocoagulation Study Group","year":"1993","unstructured":"Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol. 1993;111(9):1200\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1921_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00055735-199906000-00011","volume":"10","author":"L Wu","year":"1999","unstructured":"Wu L, Murphy RP. Photodynamic therapy: a new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration. Curr Opin Ophthalmol. 1999;10(3):217\u201320.","journal-title":"Curr Opin Ophthalmol"},{"key":"1921_CR35","doi-asserted-by":"crossref","unstructured":"Asrani S, Zeimer R, Hopkins Un The Wilmer Ophthalmological J, Wolfe Stree Wilmer N, Ro W. Feasibility of laser targeted photo-occlusion of ocular vessels. British Journal of Ophthalmology. 1995;79(8):766\u201370.","DOI":"10.1136\/bjo.79.8.766"},{"key":"1921_CR36","doi-asserted-by":"crossref","unstructured":"Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. 1994;112(4):489-499.","DOI":"10.1001\/archopht.1994.01090160065024"},{"issue":"10","key":"1921_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","author":"Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group","year":"1999","unstructured":"Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin one-year results of 2 randomized clinical trials-TAP report 1 treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol. 1999;117(10):1329\u201345.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1921_CR38","first-page":"198","volume":"119","author":"NM Bressler","year":"2001","unstructured":"Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin two-year results of 2 randomized clinical trials-TAP report 2 treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol. 2001;119(2):198\u2013207.","journal-title":"Arch Ophthalmol"},{"key":"1921_CR39","doi-asserted-by":"crossref","unstructured":"Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials\u2014TAP report no. 5. 2002;120(10):1307\u201314.","DOI":"10.1001\/archopht.120.10.1307"},{"issue":"14","key":"1921_CR40","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"1921_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000267567","volume":"27","author":"T Murata","year":"1995","unstructured":"Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27(1):48\u201352.","journal-title":"Ophthalmic Res"},{"issue":"5","key":"1921_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000268033","volume":"29","author":"LP Aiello","year":"1997","unstructured":"Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29(5):354\u201362.","journal-title":"Ophthalmic Res"},{"issue":"4","key":"1921_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cmet.2013.03.009","volume":"17","author":"A Sene","year":"2013","unstructured":"Sene A, Khan AA, Cox D, Nakamura REI, Santeford A, Kim BM, et al. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab. 2013;17(4):549\u201361.","journal-title":"Cell Metab"},{"issue":"3","key":"1921_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59030435","volume":"59","author":"Y Takamura","year":"2023","unstructured":"Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema: a descriptive review. Medicina (B Aires). 2023;59(3):435.","journal-title":"Medicina (B Aires)"},{"issue":"10","key":"1921_CR45","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1167\/iovs.02-1063","volume":"44","author":"TCB Moore","year":"2003","unstructured":"Moore TCB, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003;44(10):4457\u201364.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1921_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2337\/db14-0016","volume":"64","author":"H Huang","year":"2015","unstructured":"Huang H, He J, Johnson D, Wei Y, Liu Y, Wang S, et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with akt activation and HIF1\u03b1-VEGF pathway inhibition. Diabetes. 2015;64(1):200\u201312.","journal-title":"Diabetes"},{"key":"1921_CR47","unstructured":"Persistencemarketresearch.com. London, United Kingdom: Persistence market research. Available from: https:\/\/www.persistencemarketresearch.com\/market-research\/anti-vegf-market.asp. Published April, 2023. Accessed August 13, 2024."},{"key":"1921_CR48","unstructured":"Straitsresearch.com. Maharashtra, India: Straits Research. Available from: https:\/\/straitsresearch.com\/report\/anti-vegf-therapeutics-market. Published 2022. Accessed August 13, 2024."},{"issue":"27","key":"1921_CR49","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805\u201321.","journal-title":"N Engl J Med"},{"issue":"10","key":"1921_CR50","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","volume":"112","author":"ET Cunningham Jr","year":"2005","unstructured":"Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747\u201357.","journal-title":"Ophthalmology"},{"issue":"12","key":"1921_CR51","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1136\/bjo.2009.174946","volume":"94","author":"TR Friberg","year":"2010","unstructured":"Friberg TR, Tolentino M. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol. 2010;94(12):1611\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1921_CR52","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1167\/iovs.08-2055","volume":"49","author":"A Klettner","year":"2008","unstructured":"Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49(10):4523\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"1921_CR53","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1921_CR54","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239\u201348.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1921_CR55","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615\u201325.","journal-title":"Ophthalmology"},{"issue":"10","key":"1921_CR56","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013\u201322.","journal-title":"Ophthalmology"},{"issue":"5","key":"1921_CR57","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ajo.2014.02.019","volume":"157","author":"O Comyn","year":"2014","unstructured":"Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol. 2014;157(5):960\u201370.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1921_CR58","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results (CATT study). Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"1921_CR59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF02569055","volume":"93","author":"J Cunha-Vaz","year":"1997","unstructured":"Cunha-Vaz J. The blood-ocular barriers: past, present, and future. Doc Ophthalmol. 1997;93(1\u20132):149\u201357.","journal-title":"Doc Ophthalmol"},{"issue":"12","key":"1921_CR60","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114(12):2179\u201382.","journal-title":"Ophthalmology"},{"issue":"12","key":"1921_CR61","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"7","key":"1921_CR62","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bjophthalmol-2013-304736","volume":"98","author":"CC Wykoff","year":"2014","unstructured":"Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014;98(7):951\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"1921_CR63","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration the ARIES study: a randomized clinical trial. Retina. 2021;41(9):1911\u201320.","journal-title":"Retina"},{"issue":"11","key":"1921_CR64","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376\u201385.","journal-title":"Ophthalmology"},{"issue":"2","key":"1921_CR65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-022-00516-y","volume":"36","author":"WJA Lee","year":"2022","unstructured":"Lee WJA, Shao SC, Liao TC, Lin SJ, Lai CC, Lai ECC. Effect modification by indication to the risks of major thromboembolic adverse events in patients receiving intravitreal anti-vascular endothelial growth factor treatment: a population-based retrospective cohort study. BioDrugs. 2022;36(2):205\u201316.","journal-title":"BioDrugs"},{"issue":"9","key":"1921_CR66","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296\u2013304.","journal-title":"Ophthalmology"},{"issue":"1","key":"1921_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89\u201399.","journal-title":"Ophthalmology"},{"issue":"9","key":"1921_CR68","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","volume":"129","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Wong R, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022;129(9):974\u201385.","journal-title":"Ophthalmology"},{"issue":"12","key":"1921_CR69","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","volume":"141","author":"RP Singh","year":"2023","unstructured":"Singh RP, Barakat MR, Ip MS, Wykoff CC, Eichenbaum DA, Joshi S, et al. Efficacy and safety of brolucizumab for diabetic macular edema the KINGFISHER randomized clinical trial. JAMA Ophthalmol. 2023;141(12):1152\u201360.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"1921_CR70","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","volume":"48","author":"J Ambati","year":"2003","unstructured":"Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48(3):257\u201393.","journal-title":"Surv Ophthalmol"},{"issue":"10326","key":"1921_CR71","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"6","key":"1921_CR72","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"7","key":"1921_CR73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ophtha.2020.11.017","volume":"128","author":"RN Khurana","year":"2021","unstructured":"Khurana RN, Kunimoto D, Yoon YH, Wykoff CC, Chang A, Maturi RK, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128(7):1027\u201338.","journal-title":"Ophthalmology"},{"key":"1921_CR74","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03539549?term=NCT03539549&rank=1. Updated August 03, 2020. Accessed September 10, 2024."},{"key":"1921_CR75","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","volume":"197","author":"K Liu","year":"2019","unstructured":"Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156\u201367.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1921_CR76","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","volume":"106","author":"K Liu","year":"2022","unstructured":"Liu K, Wang H, He W, Ye J, Song Y, Wang Y, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2022;106(10):1436\u201343.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1921_CR77","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","volume":"130","author":"TL Jackson","year":"2023","unstructured":"Jackson TL, Slakter J, Buyse M, Wang K, Dugel PU, Wykoff CC, et al. A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration. Ophthalmology. 2023;130(6):588\u201397.","journal-title":"Ophthalmology"},{"key":"1921_CR78","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03397264?intr=opt-302&rank=2. Updated June 22, 2022. Accessed September 10, 2024."},{"key":"1921_CR79","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/OPTH.S232548","volume":"13","author":"JB Wingard","year":"2019","unstructured":"Wingard JB, Delzell DAP, Houlihan NV, Lin J, Gieser JP. Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration. Clin Ophthalmol. 2019;13:2563\u201372.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1921_CR80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/IJG.0000000000001499","volume":"29","author":"M G\u00f3mez-Mariscal","year":"2020","unstructured":"G\u00f3mez-Mariscal M, Mu\u00f1oz-Negrete FJ, Rebolleda Fern\u00e1ndez G. Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2020;29(6):54\u20135.","journal-title":"J Glaucoma"},{"issue":"12","key":"1921_CR81","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","volume":"120","author":"A Rasmussen","year":"2013","unstructured":"Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(12):2630\u20136.","journal-title":"Ophthalmology"},{"key":"1921_CR82","first-page":"1849","volume":"7","author":"JM Rakic","year":"2013","unstructured":"Rakic JM, Leys A, Bri\u00e9 H, Denhaerynck K, Pacheco C, Vancayzeele S, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol. 2013;7:1849\u201358.","journal-title":"Clin Ophthalmol"},{"key":"1921_CR83","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212532","volume":"7","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context. 2018;7:212532.","journal-title":"Drugs Context"},{"issue":"5323","key":"1921_CR84","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1126\/science.277.5323.242","volume":"277","author":"P Lindahl","year":"1997","unstructured":"Lindahl P, Johansson BR, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277(5323):242\u20135.","journal-title":"Science"},{"issue":"2","key":"1921_CR85","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2005.02.002","volume":"232","author":"R Erber","year":"2006","unstructured":"Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes Shih AH, et al. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006;232(2):139\u201347.","journal-title":"Cancer Lett"},{"issue":"10","key":"1921_CR86","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2011-01-331694","volume":"118","author":"M Franco","year":"2011","unstructured":"Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood. 2011;118(10):2906\u201317.","journal-title":"Blood"},{"issue":"5","key":"1921_CR87","first-page":"471","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471\u20138.","journal-title":"Mol Cancer Ther"},{"key":"1921_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aad3812","volume":"9","author":"L Roth","year":"2016","unstructured":"Roth L, Prahst C, Ruckdeschel T, Savant S, Westr\u00f6m S, Fantin A, et al. Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci Signal. 2016;9:425.","journal-title":"Sci Signal"},{"key":"1921_CR89","doi-asserted-by":"crossref","unstructured":"Fantin A, Vieira JM, Plein A, Denti L, Fruttiger M, Pollard JW, et al. Regular article vascular biology. Blood [Internet]. 2013;121(12):2352\u201362. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/121\/12\/2352\/1364788\/2352.pdf","DOI":"10.1182\/blood-2012-05-424713"},{"issue":"4","key":"1921_CR90","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cmet.2013.09.003","volume":"18","author":"A Cerani","year":"2013","unstructured":"Cerani A, Tetreault N, Menard C, Lapalme E, Patel C, Sitaras N, et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013;18(4):505\u201318.","journal-title":"Cell Metab"},{"issue":"1","key":"1921_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02761-9","volume":"23","author":"A Gyenes","year":"2023","unstructured":"Gyenes A, Istv\u00e1n L, Beny\u00f3 F, Papp A, Resch M, S\u00e1ndor N, et al. Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration. BMC Ophthalmol. 2023;23(1):14.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"1921_CR92","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","volume":"16","author":"S Stein","year":"2010","unstructured":"Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198\u2013204.\u00a0 https:\/\/doi.org\/10.1038\/nm.2088","journal-title":"Nat Med"},{"issue":"6","key":"1921_CR93","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood-2002-07-2314","volume":"101","author":"C Baum","year":"2003","unstructured":"Baum C, D\u00fcllmann J, Li Z, Fehse B, Meyer J, Williams DA, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101(6):2099\u2013114.","journal-title":"Blood"},{"key":"1921_CR94","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10948","author":"A Moraru","year":"2021","unstructured":"Moraru A, Costin D, Iorga R, Munteanu M, Moraru R, Branisteanu D. Current trends in gene therapy for retinal diseases (Review). Exp Ther Med. 2021. https:\/\/doi.org\/10.3892\/etm.2021.10948.","journal-title":"Exp Ther Med"},{"key":"1921_CR95","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejpb.2015.01.009","volume":"95","author":"C Sch\u00f6n","year":"2015","unstructured":"Sch\u00f6n C, Biel M, Michalakis S. Retinal gene delivery by adeno-associated virus (AAV) vectors: strategies and applications. Eur J Pharm Biopharm. 2015;95:343\u201352.","journal-title":"Eur J Pharm Biopharm"},{"key":"1921_CR96","doi-asserted-by":"publisher","first-page":"102394","DOI":"10.1016\/j.eclinm.2023.102394","volume":"67","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Boyer DS, Wykoff CC, Regillo CD, Busbee BG, Pieramici D, et al. Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. EClinicalMedicine. 2023;67:102394.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"1921_CR97","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamaophthalmol.2017.1571","volume":"135","author":"TL Jackson","year":"2017","unstructured":"Jackson TL, Boyer D, Brown DM, Chaudhry N, Elman M, Liang C, et al. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study. JAMA Ophthalmol. 2017;135(7):761\u20137.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"1921_CR98","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/bjophthalmol-2020-316511","volume":"105","author":"MN Cohen","year":"2021","unstructured":"Cohen MN, O\u2019Shaughnessy D, Fisher K, Cerami J, Awh CC, Salazar DE, et al. APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration. Br J Ophthalmol. 2021;105(5):716\u201322.","journal-title":"Br J Ophthalmol"},{"key":"1921_CR99","unstructured":"investors.adverum.com Redwood City, CA: Adverum Biotechnologies. Available from: https:\/\/investors.adverum.com\/press_releases\/news-details\/2024\/Adverum-Biotechnologies-Announces-Positive-52-Week-LUNA-and-4-Year-OPTIC-Results-and-Provides-Key-Pivotal-Program-Design-Elements\/default.aspx. Published November 18, 2024. Accessed January 07, 2025."},{"issue":"10436","key":"1921_CR100","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston SM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet. 2024;403(10436):1563\u201373.","journal-title":"Lancet"},{"key":"1921_CR101","unstructured":"regenxbio.gcs-web.com. Rockville, MD: Regenxbio. Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-presents-positive-one-year-data-phase-ii-altituder\/. Published November 03, 2023. Accessed January 07, 2025."},{"key":"1921_CR102","unstructured":"Pitcher JD. Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: results from the Phase II AAVIATE\u00ae Study. Hawaiian Eye and Retina. 2024. Available from: https:\/\/www.regenxbio.com\/getattachment\/09eea7b5-fa2a-4474-90e2-19d8670a6f6f\/ABBV-RGX-314-SCSwAMD-AAVIATE_Pitcher_RHE2024_FINAL_approved-(1).pdf?lang=en-US&ext=.pdf. Published January 16, 2024. Accessed: January 07, 2025."},{"key":"1921_CR103","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04704921?term=rgx-314&rank=5. Updated January 19, 2025. Accessed January 29, 2025."},{"key":"1921_CR104","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05407636?term=rgx-314&rank=4. Updated October 16, 2024. Accessed January 29, 2025."},{"key":"1921_CR105","unstructured":"4dmt.gcs-web.com. Emeryville, CA: 4D molecular therapeutics. Available from: https:\/\/4dmt.gcs-web.com\/static-files\/de51e95a-d81d-45f5-871d-e592fe3b2bda. Published September 18, 2024. Accessed January 07, 2025."},{"key":"1921_CR106","unstructured":"4dmt.gcs-web.com. Emeryville, CA: 4D molecular therapeutics. Available from: https:\/\/4dmt.gcs-web.com\/static-files\/15cda318-ccbf-4b58-81bc-2ecdb4d4907d. Published January 10, 2025. Accessed January 30, 2025."},{"key":"1921_CR107","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","volume":"177","author":"IJ Constable","year":"2017","unstructured":"Constable IJ, Lai CM, Magno AL, French MA, Barone SB, Schwartz SD, et al. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol. 2017;177:150\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"10089","key":"1921_CR108","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","volume":"390","author":"JS Heier","year":"2017","unstructured":"Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390(10089):50\u201361.","journal-title":"Lancet"},{"issue":"12","key":"1921_CR109","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ophtha.2024.06.013","volume":"131","author":"JS Heier","year":"2024","unstructured":"Heier JS, Cohen MN, Chao DL, Pepio A, Shiraga Y, Capuano G, et al. Phase 1 study of JNJ-81201887 gene therapy in geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2024;131(12):1377\u201388.","journal-title":"Ophthalmology"},{"key":"1921_CR110","unstructured":"jnjmedicalconnect.com. Available from: https:\/\/www.jnjmedicalconnect.com\/products\/jnj-81201887\/medical-content\/phase-1-clinical-trials. Updated August 14, 2024. Accessed January 25, 2025."},{"key":"1921_CR111","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04358471?term=NCT04358471&rank=1. Updated May 10, 2021. Accessed January 30, 2025."},{"issue":"5","key":"1921_CR112","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s10637-021-01093-7","volume":"39","author":"KS Pedersen","year":"2021","unstructured":"Pedersen KS, Grierson PM, Picus J, Lockhart AC, Roth BJ, Liu J, et al. Vorolanib (X-82), an oral anti-VEGFR\/PDGFR\/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase i study. Invest New Drugs. 2021;39(5):1298\u2013305.","journal-title":"Invest New Drugs"},{"issue":"12","key":"1921_CR113","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774\u201382.","journal-title":"Cancer Res"},{"issue":"4","key":"1921_CR114","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/adt.2019.920","volume":"17","author":"P Narvekar","year":"2019","unstructured":"Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-loaded poly(lactic-co-glycolic acid) nanoparticles for age-related macular degeneration: formulation development and in vitro characterization. Assay Drug Dev Technol. 2019;17(4):167\u201377.","journal-title":"Assay Drug Dev Technol"},{"issue":"37","key":"1921_CR115","doi-asserted-by":"publisher","first-page":"13379","DOI":"10.1073\/pnas.1324235111","volume":"111","author":"SS Oladipupo","year":"2014","unstructured":"Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A. 2014;111(37):13379\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1921_CR116","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/OTT.S18155","volume":"4","author":"MS Ballas","year":"2011","unstructured":"Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther. 2011;4:43\u201358.","journal-title":"Onco Targets Ther"},{"key":"1921_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107775","volume":"187","author":"Z Dong","year":"2019","unstructured":"Dong Z, Santeford A, Ban N, Lee TJ, Smith C, Ornitz DM, et al. FGF2-induced STAT3 activation regulates pathologic neovascularization. Exp Eye Res. 2019;187:107775.","journal-title":"Exp Eye Res"},{"issue":"9","key":"1921_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025668","volume":"6","author":"I Domingues","year":"2011","unstructured":"Domingues I, Rino J, Demmers JAA, de Lanerolle P, Santos SCR. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS ONE. 2011;6(9):e25668.","journal-title":"PLoS ONE"},{"issue":"10","key":"1921_CR119","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008979","volume":"5","author":"G Carpenter","year":"2013","unstructured":"Carpenter G, Liao HJ. Receptor tyrosine kinases in the nucleus. Cold Spring Harb Perspect Biol. 2013;5(10):a008979.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"1921_CR120","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/cells3020363","volume":"3","author":"HM Jopling","year":"2014","unstructured":"Jopling HM, Odell AF, Pellet-Many C, Latham AM, Frankel P, Sivaprasadarao A, et al. Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase regulates endothelial function and blood vessel formation. Cells. 2014;3(2):363\u201385.","journal-title":"Cells"},{"key":"1921_CR121","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bcp.2017.04.006","volume":"136","author":"LE Kilpatrick","year":"2017","unstructured":"Kilpatrick LE, Friedman-Ohana R, Alcobia DC, Riching K, Peach CJ, Wheal AJ, et al. Real-time analysis of the binding of fluorescent VEGF165a to VEGFR2 in living cells: effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes. Biochem Pharmacol. 2017;136:62\u201375.","journal-title":"Biochem Pharmacol"},{"key":"1921_CR122","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7355039","volume":"2023","author":"X Cao","year":"2023","unstructured":"Cao X, Li T, Tian Y, Tian Y, Gao C, Zhang D, et al. BIBF1120 protects against diabetic retinopathy through neovascularization-related molecules and the MAPK signaling pathway. J Ophthalmol. 2023;2023:7355039.","journal-title":"J Ophthalmol"},{"key":"1921_CR123","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5905269","volume":"2020","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhu M, Xie L, Sun X, Xu J, Guo Y, et al. Cabozantinib, a multityrosine kinase inhibitor of MET and VEGF receptors which suppresses mouse laser-induced choroidal neovascularization. J Ophthalmol. 2020;2020:5905269.","journal-title":"J Ophthalmol"},{"issue":"2","key":"1921_CR124","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0025-6196(11)60847-1","volume":"83","author":"T Diago","year":"2008","unstructured":"Diago T, Pulido JS, Molina JR, Collet LC, Link TP, Ryan EH. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc. 2008;83(2):231\u20134.","journal-title":"Mayo Clin Proc"},{"key":"1921_CR125","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: \u201cis there a big change on the horizon?\u201d Clin Ophthalmol. 2018;12:2137\u201343.","journal-title":"Clin Ophthalmol"},{"key":"1921_CR126","unstructured":"lincs.hms.harvard.edu. Available from: https:\/\/lincs.hms.harvard.edu\/db\/sm\/10175-106\/. Updated March 30, 2018. Accessed October 02, 2024."},{"key":"1921_CR127","unstructured":"fda.gov. Silver Spring, MD: US Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021938s033lbl.pdf. Published August 16, 2018. Accessed August 28, 2024."},{"key":"1921_CR128","unstructured":"ema.europa.eu. Amsterdam, The Netherlands: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sutent. Updated August 13, 2021. Accessed August 28, 2024."},{"issue":"5","key":"1921_CR129","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"JT Hartmann","year":"2009","unstructured":"Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470\u201381.","journal-title":"Curr Drug Metab"},{"key":"1921_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00367","volume":"8","author":"F Paech","year":"2017","unstructured":"Paech F, Bouitbir J, Kr\u00e4henb\u00fchl S. Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol. 2017;8:367.","journal-title":"Front Pharmacol"},{"key":"1921_CR131","unstructured":"businesswire.com. San Francisco, CA: Business wire. Available from: https:\/\/www.businesswire.com\/news\/home\/20190121005424\/en\/Graybug-Vision-Presents-Top-Line-Results-of-Phase-12a-ADAGIO-Study-at-Hawaiian-Eye-Retina-2019. Published January 21, 2019. Accessed August 25, 2024."},{"key":"1921_CR132","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04085341?cond=Age-Related%20Macular%20Degeneration&intr=sunitinib&rank=3&tab=results#adverse-events. Updated November 22, 2021. Accessed August 25, 2024."},{"key":"1921_CR133","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03953079?tab=results. Updated January 19, 2022. Accessed August 26, 2024."},{"key":"1921_CR134","unstructured":"Hutton, D. Preliminary topline results from phase 2b ALTISSIMO trial unveiled. Opthalmology Times. 2021. Available from: https:\/\/www.ophthalmologytimes.com\/view\/preliminary-topline-results-from-phase-2b-altissimo-trial-unveiled. Published May 10, 2021. Accessed August 22, 2024."},{"issue":"4","key":"1921_CR135","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1634\/theoncologist.2018-0740","volume":"24","author":"JC Bendell","year":"2019","unstructured":"Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, et al. Phase I, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of vorolanib in patients with advanced solid tumors. Oncologist. 2019;24(4):455-e121.","journal-title":"Oncologist"},{"issue":"15","key":"1921_CR136","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1038\/s41433-023-02496-x","volume":"37","author":"Y Gao","year":"2023","unstructured":"Gao Y, Lu F, Li X, Dai H, Liu K, Liu X, et al. Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase i, open-label study. Eye. 2023;37(15):3228\u201333.","journal-title":"Eye"},{"key":"1921_CR137","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03710863?cond=Age-Related%20Macular%20Degeneration&intr=x-82&rank=2. Updated January 13, 2020. Accessed September 24, 2024."},{"key":"1921_CR138","unstructured":"eyepointpharma.com. Watertown, MA: EyePoint Pharmaceuticals. Available from: https:\/\/eyepointpharma.com\/trial\/phase-2-davio-2-clinical-trial-topline-results\/. Published 2023. Accessed September 16, 2024."},{"key":"1921_CR139","unstructured":"investors.eyepointpharma.com Watertown, MA: EyePoint Pharmaceuticals. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-announces-positive-six-month-results-phase-2-veronabiospace.com. Published February 05, 2025. Accessed February 24, 2025."},{"key":"1921_CR140","unstructured":"biospace.com. West Des Moines, IA: BioSpace. Available from: https:\/\/www.biospace.com\/article\/releases\/eyepoint-pharmaceuticals-announces-topline-data-from-the-phase-2-pavia-trial-of-duravyu-in-non-proliferative-diabetic-retinopathy\/. Published May 06, 2024. Accessed September 17, 2024."},{"key":"1921_CR141","unstructured":"lincs.hms.harvard.edu. Available from: https:\/\/lincs.hms.harvard.edu\/db\/sm\/10443-101\/. Updated April 04, 2016. Accessed October 02, 2024."},{"key":"1921_CR142","unstructured":"Kaiser PK, Ciulla T, Kansara V. Suprachoroidal CLS-AX (axitinib injectable suspension), as a potential long-acting therapy for neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2020. Available from: https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2768322. Published June, 2020. Accessed October 10, 2024."},{"key":"1921_CR143","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04626128?intr=axitinib&cond=Age-Related%20Macular%20Degeneration&rank=4. Updated September 18, 2023. Accessed September 14, 2024."},{"key":"1921_CR144","unstructured":"Koennecke, G. Clearside Biomedical Presents New Data from CLS-AX ODYSSEY Phase 2b Trial. Opthalmology Times. 2025. Available from: https:\/\/www.ophthalmologytimes.com\/view\/clearside-biomedical-presents-new-data-from-cls-ax-odyssey-phase-2b-trial. Published February 11, 2025. Accessed February 24, 2025."},{"key":"1921_CR145","unstructured":"glance.eyesoneyecare.com. San Diego, CA: Eyes on Eyescare. Available from: https:\/\/glance.eyesoneyecare.com\/stories\/2023-06-13\/ocular-therapeutix-releases-12-month-topline-data-from-phase-1-wet-amd-trial\/. Published June 13, 2023. Accessed September 15, 2024."},{"key":"1921_CR146","unstructured":"clinicaltrials.gov. Bethesda, MD: National Institutes of Health. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04989699?intr=axitinib&cond=Age-Related%20Macular%20Degeneration&rank=5. Updated January 26, 2024. Accessed September 14, 2024."},{"key":"1921_CR147","unstructured":"lincs.hms.harvard.edu. Available from: https:\/\/lincs.hms.harvard.edu\/db\/sm\/10151-101\/. Updated April 04, 2016. Accessed October 02, 2024."},{"issue":"8","key":"1921_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218632","volume":"14","author":"M Hatano","year":"2019","unstructured":"Hatano M, Tokuda K, Kobayashi Y, Yamashiro C, Uchi SH, Kobayashi M, et al. Inhibitory effect of nintedanib on VEGF secretion in retinal pigment epithelial cells induced by exposure to a necrotic cell lysate. PLoS ONE. 2019;14(8):e0218632.","journal-title":"PLoS ONE"},{"key":"1921_CR149","unstructured":"lincs.hms.harvard.edu. Available from: https:\/\/lincs.hms.harvard.edu\/db\/sm\/10008-101\/. Updated April 04, 2016. Accessed October 02, 2024."},{"key":"1921_CR150","doi-asserted-by":"crossref","unstructured":"Comparison of age-related macular degeneration treatments trials (CATT) research group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"1921_CR151","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1921_CR152","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126(8):1155\u201370.","journal-title":"Ophthalmology"},{"issue":"9","key":"1921_CR153","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):964\u201372.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"1921_CR154","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","volume":"117","author":"QD Nguyen","year":"2010","unstructured":"Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146\u201351.","journal-title":"Ophthalmology"},{"key":"1921_CR155","doi-asserted-by":"crossref","unstructured":"Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science (1979). 2007 Jul 27;317(5837):477.","DOI":"10.1126\/science.1142658"},{"issue":"2","key":"1921_CR156","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler RJ, La Fave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015;125(2):870\u201380.","journal-title":"J Clin Invest"},{"issue":"8","key":"1921_CR157","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"issue":"12","key":"1921_CR158","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","volume":"22","author":"PB Shieh","year":"2023","unstructured":"Shieh PB, Kuntz NL, Dowling JJ, M\u00fcller-Felber W, B\u00f6nnemann CG, Seferian AM, et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023;22(12):1125\u201339.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1921_CR159","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/aos.15101","volume":"100","author":"L Lorenzo-Soler","year":"2022","unstructured":"Lorenzo-Soler L, Praphanwittaya P, Olafsdottir OB, Kristinsdottir IM, Asgrimsdottir GM, Loftsson T, et al. Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye. Acta Ophthalmol. 2022;100(7):788\u201396.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"1921_CR160","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.xphs.2019.10.007","volume":"109","author":"L Zhao","year":"2020","unstructured":"Zhao L, Tang B, Tang P, Sun Q, Suo Z, Zhang M, et al. Chitosan\/sulfobutylether-\u03b2-cyclodextrin nanoparticles for ibrutinib delivery: a potential nanoformulation of novel kinase inhibitor. J Pharm Sci. 2020;109(2):1136\u201344.","journal-title":"J Pharm Sci"},{"key":"1921_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107110","volume":"144","author":"X Xiu","year":"2024","unstructured":"Xiu X, Li M, Hu D, Jia H, Wang H, Liu Y, et al. Potential oral VEGFR2 inhibitors: treatment of wet age-related macular degeneration. Bioorg Chem. 2024;144:107110.","journal-title":"Bioorg Chem"},{"issue":"13","key":"1921_CR162","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203.","journal-title":"N Engl J Med"},{"issue":"10","key":"1921_CR163","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1167\/iovs.06-0433","volume":"47","author":"RA Costa","year":"2006","unstructured":"Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LAS, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47(10):4569\u201378.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1921_CR164","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/IAE.0b013e31827b63f3","volume":"33","author":"LP Cintra","year":"2023","unstructured":"Cintra LP, Costa RA, Ribeiro JAS, Calucci D, Scott IU, Messias A, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) 1-year results. Retina. 2023;33(6):1109\u201316.","journal-title":"Retina"},{"issue":"7761","key":"1921_CR165","first-page":"1398","volume":"340","author":"A Tufail","year":"2010","unstructured":"Tufail A, Patel PJ, Egan C, Hykin P, Da Cruz L, Gregor Z, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ (Online). 2010;340(7761):1398.","journal-title":"BMJ (Online)"},{"issue":"8","key":"1921_CR166","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","volume":"130","author":"R Rajendram","year":"2012","unstructured":"Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1921_CR167","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2015.11.021","volume":"123","author":"HE Wiley","year":"2016","unstructured":"Wiley HE, Thompson DJS, Bailey C, Chew EY, Cukras CA, Jaffe GJ, et al. A crossover design for comparative efficacy: a 36-week randomized trial of bevacizumab and ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(4):841\u20139.","journal-title":"Ophthalmology"},{"issue":"6","key":"1921_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2020.9291","volume":"20","author":"D Benisek","year":"2020","unstructured":"Benisek D, Manzitti J, Scorsetti D, Rousselot Ascarza A, Ascarza A, Gomez Ranca\u00f1o D, et al. Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere®) in patients with neovascular age-related macular degeneration. Exp Ther Med. 2020;20(6):1\u20131.","journal-title":"Exp Ther Med"},{"issue":"10","key":"1921_CR169","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/jop.2018.0062","volume":"34","author":"D Callanan","year":"2018","unstructured":"Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, et al. Double-masked, randomized, phase 2 evaluation of abicipar pegol (an anti-VEGF DARPin therapeutic) in neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2018;34(10):700\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"1921_CR170","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121(9):1740\u20137.","journal-title":"Ophthalmology"},{"key":"1921_CR171","doi-asserted-by":"crossref","unstructured":"Patel S, Storey PP, Barakat MR, Hershberger V, Bridges WZ Jr, Eichenbaum DA, et al. Phase I DAVIO trial: EYP-1901 bioerodible, sustained-delivery vorolanib insert in patients with wet age-related macular degeneration. Ophthalmol Sci. 2024;4(5):100527.","DOI":"10.1016\/j.xops.2024.100527"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01921-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01921-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01921-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:08:28Z","timestamp":1789398508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01921-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,12]]},"references-count":171,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01921-1","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,12]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}